Drug intelligence / Profile preview

gallium-68 bisphosphonate

Development stage
Preclinical
Lead developer
Mayo Clinic
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[68Ga]Ga-BP (gallium-68 buffered phosphate) is a novel, small-molecule positron emission tomography (PET) imaging radiotracer developed by the Mayo Clinic for the non-invasive detection and differentiation of bacterial infections (such as osteomyelitis) from sterile inflammation. The tracer is designed to exploit the bacterial requirement for iron; due to the similar size and charge of gallium (Ga3+) to iron (Fe3+), gallium-68 acts as an iron surrogate and is directly taken up by bacteria via membrane-bound transferrin receptors and siderophore-mediated transport systems. Preclinical studies in rat models of foreign body-associated osteomyelitis caused by MRSA, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae* have demonstrated that [68Ga]Ga-BP can successfully identify active bacterial infections with high specificity, outperforming conventional tracers like [18F]FDG and [68Ga]Ga-citrate.

Other names
Ga-BP[68Ga]Ga-BPgallium-68 buffered phosphategallium68 buffered phosphategallium 68 buffered phosphategallium-68 phosphategallium68 phosphategallium 68 phosphate
02

Targets

TbpA-TbpB (Bacterial transferrin receptor complex)FepA (Ferric enterobactin receptor FepA)

Beyond the preview

Go deeper on gallium-68 bisphosphonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium-68 bisphosphonate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call